Antiplatelet and oral anticoagulant therapies in chronic hemodialysis patients: prescribing practices and bleeding risk.
Fiche publication
Date publication
août 2016
Journal
Pharmacoepidemiology and drug safety
Auteurs
Membres identifiés du Cancéropôle Est :
Pr THILLY Nathalie
Tous les auteurs :
Collette C, Clerc-Urmès I, Laborde-Castérot H, Frimat L, Ayav C, Peters N, Martin A, Agrinier N, Thilly N
Lien Pubmed
Résumé
Results of previous studies assessing the risk of bleeding associated with prescription of antiplatelet (AP) and/or oral anticoagulant (AC) therapy to hemodialysis patients are conflicting. Our purpose was to describe practices for prescription of AP and AC in hemodialysis patients in the Lorraine region, and to assess their effect on the risk of major bleeding events.
Mots clés
Administration, Oral, Adult, Aged, Aged, 80 and over, Anticoagulants, administration & dosage, Cohort Studies, Drug Therapy, Combination, Female, Follow-Up Studies, Hemorrhage, chemically induced, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, administration & dosage, Probability, Proportional Hazards Models, Renal Dialysis, methods, Renal Insufficiency, Chronic, therapy, Retrospective Studies, Risk
Référence
Pharmacoepidemiol Drug Saf. 2016 Aug;25(8):935-43